Pascal Soriot

Pascal Soriot is a French-born executive who has served as the chief executive officer of the Anglo-Swedish pharmaceutical and biotechnology company AstraZeneca since 2012. His tenure is widely credited with transforming the company's fortunes through a strategic focus on oncology, cardiovascular disease, and respiratory disease research, leading to a period of significant growth and a robust product pipeline. Soriot previously held senior roles at the Swiss healthcare giant Roche and its subsidiary Genentech.

Early life and education

Born in Boulogne-Billancourt, a suburb of Paris, he initially pursued a career in veterinary medicine. He earned a Doctor of Veterinary Medicine degree from the prestigious École Nationale Vétérinaire d'Alfort in France. Seeking a broader business perspective, he later completed a Master of Business Administration at the renowned HEC Paris, one of Europe's leading business schools. This dual background in life sciences and corporate management provided a strong foundation for his subsequent career in the global healthcare industry.

Career at Roche

Soriot began his pharmaceutical career at the Roussel-Uclaf company before joining Roche in 1986. He held various commercial and general management positions across different regions, including Asia-Pacific and North America, gaining extensive international experience. A pivotal move came in 2002 when he was appointed Chief Operating Officer of Genentech, Roche's critically important biotechnology subsidiary based in South San Francisco. He played a key role in the successful integration of Genentech following Roche's full acquisition of the company, helping to drive the launch of major products like the cancer drug Avastin.

Tenure at AstraZeneca

He was appointed CEO of AstraZeneca in October 2012, succeeding David Brennan during a challenging period marked by patent expirations for key drugs like Crestor and Nexium. One of his earliest and most defining moments was his firm rejection of a major takeover bid from the American rival Pfizer in 2014, arguing the offer undervalued the company's future prospects. He subsequently implemented a bold strategy to rebuild AstraZeneca's research and development pipeline, making significant investments in oncology through acquisitions like that of MedImmune and partnerships with firms like Daiichi Sankyo. His leadership during the COVID-19 pandemic was globally prominent, overseeing the rapid development and distribution of the COVID-19 vaccine developed with the University of Oxford.

Leadership and business strategy

His leadership philosophy is characterized by a deep commitment to scientific innovation and a long-term strategic vision. He reorganized AstraZeneca into three core therapy areas: Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. This focus was supported by major business development deals, including the landmark collaboration with Daiichi Sankyo on the antibody-drug conjugate Enhertu. He has consistently emphasized the importance of corporate culture and talent management, often stating that the company's success is driven by its people. His approach has transformed AstraZeneca from a company facing decline into one of the world's most valuable pharmaceutical companies.

Awards and recognition

For his contributions to the pharmaceutical industry and global health, he has received numerous accolades. He was appointed an Honorary Commander of the Order of the British Empire in the 2022 Birthday Honours for services to UK life sciences and the COVID-19 response. He has been frequently listed among the most influential people in global healthcare by publications like Forbes and Fortune. In 2021, he received the Scrip Award for Executive of the Year, and AstraZeneca's COVID-19 vaccine work was recognized with the Princess of Asturias Award for Technical and Scientific Research.

Category:1959 births Category:Living people Category:French chief executives Category:French businesspeople in healthcare Category:AstraZeneca people